GE HealthCare Technologies Inc. Earnings Per Share Disclosure
| Earnings Per Share | For the years ended December 31 | ||||||||||
| (In millions, except per share amounts) | 2025 | 2024 | 2023 | ||||||||
| Numerator: | |||||||||||
| Net income from continuing operations | $ | 2,154 | $ | 2,050 | $ | 1,618 | |||||
Net (income) loss attributable to noncontrolling interests | (70) | (57) | (46) | ||||||||
Net income from continuing operations attributable to GE HealthCare | 2,084 | 1,993 | 1,572 | ||||||||
| Deemed preferred stock dividend of redeemable noncontrolling interest | — | — | (183) | ||||||||
Net income from continuing operations attributable to GE HealthCare common stockholders | 2,084 | 1,993 | 1,389 | ||||||||
Income (loss) from discontinued operations, net of taxes | — | — | (4) | ||||||||
Net income attributable to GE HealthCare common stockholders | $ | 2,084 | $ | 1,993 | $ | 1,385 | |||||
| Denominator: | |||||||||||
| Basic weighted-average shares outstanding | 456 | 456 | 455 | ||||||||
| Dilutive effect of common stock equivalents | 1 | 2 | 3 | ||||||||
| Diluted weighted-average shares outstanding | 458 | 459 | 458 | ||||||||
| Basic Earnings Per Share: | |||||||||||
Continuing operations | $ | 4.56 | $ | 4.37 | $ | 3.06 | |||||
| Discontinued operations | — | — | (0.01) | ||||||||
| Attributable to GE HealthCare common stockholders | 4.56 | 4.37 | 3.05 | ||||||||
| Diluted Earnings Per Share: | |||||||||||
Continuing operations | $ | 4.55 | $ | 4.34 | $ | 3.04 | |||||
| Discontinued operations | — | — | (0.01) | ||||||||
| Attributable to GE HealthCare common stockholders | 4.55 | 4.34 | 3.03 | ||||||||
Antidilutive securities(1) | 3 | 3 | 4 | ||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 4, 2026 | Showing above |
| 2024 | Feb 13, 2025 | |
| 2023 | Feb 6, 2024 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.